$TTRX News

WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10

U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat

A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…

LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24

WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics: Small Market Cap, Huge Potential

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout

Turn Therapeutics’ stock jumps on AD data and trial expansion

Why Is Turn Therapeutics Stock Trading Higher Today?

Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis